Moreover, a large genetic screening in participants of the Framingham Heart Study revealed that rare and subtle heterozygous mutations of the SLC12A1 gene, protect against hypertension, further proving that factors regulating the activity of NKCC2 are key determinants of the control of BP in the general population [16,17]. This evidence concerns the gene SLC12A1 and Hypertension.